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Diabetes mellitus is a complex, chronic disease requiring routine 
monitoring of glycaemic control to minimise, avoid or delay asso­
ciated complications. Diabetes is an important contributor to the 
burden of disease in South Africa (SA), with an estimated prevalence 
of 6.5% for adults between 20 and 79 years of age.[1] 
In the SA public sector, random blood glucose is commonly 
used to make clinical decisions with regard to glycaemic control, as 
glyco sylated haemoglobin (HbA1c) tests have either not been done, 
or the results are not yet available or are out of date. The most suit­
able value of random blood glucose to predict control (HbA1c <7%) 
is 9.8 mmol/L, with a sensitivity of 77% and a specificity of 75%,[2] 
which implies that even in the best of circumstances the assessment 
of control will be incorrect in up to a quarter of patients. 
SA guidelines recommend that HbA1c be checked every 6 months 
in well­controlled patients and every 3 months in uncontrolled ones 
or whenever treatment changes.[3] Small but sustained reductions in 
HbA1c can lead to a significant decrease in the risk of complications.[4]
The American Diabetes Association recommends the use of 
point­of­care (POC) testing for HbA1c to allow for timely decisions 
with regard to therapeutic changes.[5] POC testing for HbA1c has 
evolved with the availability of relatively cheap, reliable and accurate 
instruments.[6] Research has shown that availability of test results 
during the same visit is associated with improvement in glycaemic 
control, even in poor urbanised communities.[7,8] POC testing can 
improve collaboration between the patient and provider for manage­
ment of the disease[9] and lead to immediate counselling and 
treatment adjustment.[10] It can save the patient time by reducing the 
number of clinic visits and save the practitioner the administration 
time of obtaining laboratory results telephonically, reviewing patient 
records or mailing the results to the patient.[10] POC testing has also 
been found to be acceptable and feasible to physicians and other staff 
members.[10] It has been associated with improved patient experience 
and satisfaction.[9] Despite these advantages, the cost of POC testing 
may be up to three times that of the normal laboratory service.[7]
Most of the research has been performed in high­resource settings. 
There is little evidence of whether such testing can achieve similar 
benefits for patients in low­resource settings or whether investing 
in POC testing would be a cost­effective strategy. In our setting, the 
Western Cape Department of Health was interested in a feasibility 
study to assess the technical quality, costs and consequences of POC 
testing for HbA1c in primary care.
This study, therefore, aimed to evaluate the costs and consequences 
of introducing POC testing for HbA1c in patients with type 2 dia­
betes mellitus at community health centres in the Western Cape, 
with the ultimate objective of improving their glycaemic control and 
quality of care.
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Background. Diabetes mellitus contributes significantly to the burden of disease in South Africa (SA). Monitoring of glycaemic control with 
glycosylated haemoglobin (HbA1c) is recommended, even though current laboratory­based testing does not support immediate clinical 
decision­making. 
Objectives. To evaluate the costs and consequences for quality of care by introducing point­of­care (POC) testing for HbA1c for patients 
with type 2 diabetes at community health centres in Cape Town, SA. 
Methods. A quasi­experimental study was conducted at two control and two intervention sites in the same sub­district. The DCA Vantage 
Analyzer (Siemens, Germany) for POC testing was introduced at the intervention sites for 12 months. Patients were randomly selected 
from the diabetes register at the intervention (n=300) and control (n=300) sites, respectively, and data were collected from patient records 
at baseline and 12 months. Focus group interviews were performed at the intervention sites. Technical quality and cost implications were 
evaluated.
Results. POC testing was feasible, easy to integrate into the organisation of care, resulted in more immediate feedback to patients (p<0.001) 
and patients appeared more satisfied. POC testing did not improve test coverage, treatment intensification, counselling or glycaemic control. 
There was an incremental cost of ZAR2 110 per 100 tests. Compliance with quality control was poor, although control tests showed good 
reliability. 
Conclusion. This study does not support the introduction of POC testing for HbA1c in public sector primary care practice in the current 
context. POC testing should be evaluated further in combination with interventions to overcome clinical inertia and strengthen primary 
healthcare.
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This was a quasi­experimental study that compared POC testing in 
two purposively selected community health centres with two similar 
health centres that offered usual care in the same sub­district.
Setting
The study was performed in the Helderberg sub­district of the Cape 
Town metropole. In the public sector, patients attend community 
health centres for management of their diabetes on specific ‘club’ 
days. On arrival they obtain their folder and have routine tests 
performed in the preparation room. They are then seen by either a 
clinical nurse practitioner or a doctor, if poorly controlled. 
A laboratory HbA1c is meant to be checked once a year. Audits 
suggest that 70% of patients currently receive the test.[11] Laboratory 
results are returned to the health centre for filing in the patients’ 
records. The results are usually considered when the patients are next 
reviewed after 3 ­ 6 months.
Study population
The study population consisted of adult patients (>18 years of age) 
with type 2 diabetes mellitus, who had been attending the community 
health centres for at least a year.
Sample size calculation
A sample size calculation, based on having 90% power to detect a 1% 
difference in HbA1c (standard deviation (SD) 2.23) with a p­value 
of <0.05 considered significant, suggested that 106 patients were 
required in each group (n=212). To compensate for those without 
an HbA1c test result at baseline and for loss to follow up, a sample 
consisting of 300 patients in each group was selected.
Selection of health centres and patients
The community health centres were chosen from the same sub­
district and therefore served similar communities. Selection of the 
intervention sites was based on the presence of a family medicine 
registrar at each site to assist with implementation of the POC testing, 
and the control sites were selected to be as similar as possible in terms 
of the service provided. The two registrars also performed the duties 
of research assistants. 
At each health centre, 150 patient records were randomly selected 
from the club register using computer­generated random numbers. 
The staff at the health facilities were not aware of the identity of 
patients who were selected for the study.
Intervention
The DCA Vantage Analyzer (Siemens, Germany) for POC testing was 
used in this study (Fig. 1). It has a time to HbA1c result of 6 minutes 
and is able to detect results within the range of 2.5 ­ 14%. 
At the intervention sites, 2 ­ 3 members of the chronic care team 
were trained by Siemens staff to operate the POC machine and 
received competency certificates. The location of the POC machine 
and its integration into the process of care were negotiated with the 
local chronic care teams.
POC testing was performed according to a standardised operating 
procedure, with the goal of one test per patient over 12 months. 
Additional tests could be performed if the doctor felt it was clinically 
necessary. POC testing was discontinued after 12 months.
The HbA1c test result was entered into the patient record; the 
patient was then managed according to the usual guidelines and 
practice at the health facility. No attempt was made to provide 
additional training in the management of diabetes and interpretation 
of the HbA1c test.
The technical quality of the POC machine was assessed using 
weekly internal quality control measures, which involved control 
reagents, and monthly external quality control, comparing the POC 
test result with the laboratory result with regard to the same patient 
during the same visit. 
Data collection
Data were collected retrospectively at baseline and 12 months later 
from the medical records to assess HbA1c testing, medication use 
and counselling over the preceding year. Demographic and clinical 
data were also collected at baseline. Data for quality control were 
obtained from the register kept with the POC machine. HbA1c 
results of all patients were obtained at 18 months from the laboratory 
database. At the end of the study, focus group interviews were 
conducted by an independent researcher with the chronic care teams 
at the intervention sites to explore their experience of using the POC 
machine. Data were also collected on the incremental cost of salaries 
(staff time) and resources used.
Data analysis
Data were entered into an Excel (Microsoft, USA) spreadsheet 
and checked prior to analysis by the Biostatistics Unit, Faculty 
of Medicine and Health Sciences, Stellenbosch University, using 
Statistica 13.0 (Dell, USA).
Descriptive statistics reported on frequencies and percentages 
or means and SDs. Both categorical and continuous data were 
paired at baseline and follow­up and any change in category or 
numerical difference was evaluated. Inferential statistics were then 
used to compare the differences between the intervention and control 
groups. Pearson’s χ2 test was used to compare categorical variables 
between the two groups. Continuous numerical data were analysed 
using the t­test of proportion, if normally distributed. If not normally 
distributed, the two­sample Wilcoxon rank­sum (Mann­Whitney) 
test was used for analysis. 
The cost of testing was analysed based on the time taken to 
perform the test and the salary of the nurse performing it, as well as 
the costs of all materials used. These costs were then compared with 
Fig. 1. The DCA Vantage Analyzer for POC testing in a primary care facility.
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those of laboratory testing and costs saved by not performing the 
random blood glucose tests. 
Qualitative data were transcribed verbatim and checked against 
the original audio recording. Data were then analysed using the 
framework method (familiarisation, thematic index, coding, chart­
ing, interpretation).
Ethical considerations
The Health Research Ethics Committee, Stellenbosch University 
approved the study (ref. no.: N13/02/026). Permission to conduct the 
study was obtained from the Western Cape Department of Health 
and the facility managers of the health facilities.
Results
Study sample
Data of patients with type 2 diabetes were obtained from the four 
community health centres (n=600), from the intervention sites 
(n=300), and from the control sites (n=300). The mean age of the 
patients in the study sample was 56.7 (SD 13.0) years and 385 (64.2%) 
were females. Table 1 presents a profile of key diabetes indicators in 
the study sample.
Table 2 indicates differences in healthcare workers’ use of HbA1c 
testing in both groups. There was a statistical difference in terms 
of the frequency of testing, which was the primary outcome of the 
study; however, this was because fewer people in the control group 
were being tested. At follow­up, there were 139 (46.3%) patients in 
the intervention group who received their result on the same day 
compared with 0 (0.0%) patients in the control group (p<0.001). The 
mean turnaround time for the test result decreased in both groups, 
but on follow­up it was significantly lower in the POC group (mean 
10.1 v. 63.6 days; p<0.001). POC testing, therefore, resulted in more 
immediate feedback to the patients with regard to the level of their 
glycaemic control. Glycaemic control, however, was not significantly 
improved in the POC group at 18 months from baseline.
There was no significant improvement in the number of additional 
patients who received metformin, gliclazide, glibenclamide, prota­
phane or actraphane in the intervention group and no significant 
increase in the mean dose of these medications.
In the control group, 25 (8.3%) additional patients were referred for 
counselling compared with 5 (1.7%) fewer in the intervention group 
(p=0.007). There was no difference in patients counselled in the con­
sultation (control group 38 (12.7%) additional patients v. intervention 
group 28 (9.3%) additional patients; p=0.736). There was therefore no 
positive effect on patient education and counselling in the POC group 
receiving immediate feedback on glycaemic control.
Technical quality
For the internal quality assessment of the expected tests, only 25 
of 104 (24.0%) of the normal controls and 27 of 104 (26.0%) of the 
abnormal controls were included. All the values (100%) of the control 
tests were within the acceptable range for normal (4.2 ­ 6.4%) and 
abnormal (8.9 ­ 13.3%) controls. The mean HbA1c result for the 
normal control values was 5.3%, with an SD of 0.42, while the mean 
for the abnormal control values was 10.8%, with an SD of 0.29.
For the external quality assessment only 6 of 24 (25.0%) of the 
expected tests were performed. The Spearman correlation coefficient 
between the laboratory tests and POC test results in the external 
quality assessment was 0.80, indicating a strong association.








Age (years) 56.7 (13.0) 55.0 (13.1) 58.5 (12.6)
Body mass index (kg/m2) 32.1 (6.9) 32.8 (6.9) 31.4 (6.8)
HbA1c (%) 9.1 (2.5) 8.8 (2.3) 9.4 (2.6)
Random blood glucose (mmol/L) 10.4 (4.7) 11.1 (5.1) 9.7 (4.2)
Systolic blood pressure (mmHg) 144.9 (24.4) 147.3 (25.4) 142.4 (23.2)
Diastolic blood pressure (mmHg) 82.7 (12.6) 83.3 (14.0) 82.1 (11.1)
Total cholesterol (mmol/L) 5.1 (1.2) 5.0 (1.1) 5.1 (1.4)
Creatinine (µmol/L) 81.6 (68.5) 74.6 (51.8) 89.6 (82.9)
n (%) n (%) n (%)
Female 385 (64.2) 192 (64.0) 193 (64.3)
Male 215 (35.8) 108 (36.0) 107 (35.7)
Table 2. Comparing HbA1c testing in intervention and control groups
Variable
Change in intervention 
group (n=300), n (%)
Change in control group 
(n=300), n (%) p-value
Additional HbA1c tests done 4 (1.3) −24 (8.0) 0.007
Additional patients having >1 HbA1c test performed 4 (1.3) 0 (0.0) 0.297
Mean (SD) Mean (SD)
Mean difference in HbA1c result (%) at 12 months −0.44 (1.8) 0.13 (2.1) 0.032
Mean difference in HbA1c result (%) at 18 months 0.00 (1.5) 0.50 (2.0) 0.107
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Cost analysis
The calculation assumes that intravenous blood must still be drawn 
annually to test for cholesterol and creatinine, a glucometer will still 
be needed, and transport costs remain the same for other specimens. 
The costs of printing the laboratory results on paper, delivering it to 
the health centre and filing the results were not included. The cost of 
electricity to run the machine was difficult to calculate and was not 
included, but would not add significantly to the cost. POC testing 
was thought not to increase the cost of medical waste disposal for 
the facility. The cost of some patients returning for an additional visit 
to obtain their result was also not included. Most patients receive 
their result at their next routine visit. The additional time taken to 
perform the POC test (4 minutes) was partially offset by the time 
saved by not performing the finger­prick random blood glucose test 
during that visit (2 minutes). Overall, therefore, the testing would 
require an additional ZAR21.10 per patient per year. These costs may 
be considerably less if the HbA1c cartridges are purchased in bulk. 
Although the cost of the POC instrument is included, it is usually 
incorporated into the purchase cost of the cartridges.
Observations and feedback from staff
One of the sites had to replace the POC analyser, as it was faulty 
during the study, and both sites experienced brief periods without a 
supply of cartridges. Staff reported that the POC analyser was easy 
to use and integrate into the clinic. They felt that patients benefited 
from a reduced number of visits and having their treatment modified 
immediately. Although the analyser took 6 minutes to process the 
sample, the staff performed other tasks during that time. The register 
of HbA1c results that was kept with the machine was useful for 
clinical governance. Patients appeared more satisfied because the 
quality of service was visibly improving, they received immediate 
feedback on their glycaemic control, and a venous sample did not 
have to be taken. Staff believed that seeing the test performed and 
receiving the result immediately helped to motivate lifestyle change. 
Staff expressed a desire for a POC analyser that would also measure 
cholesterol and creatinine.
Discussion
POC testing for HbA1c resulted in significantly more immediate 
feedback to patients about their glycaemic control. However, it did 
not lead to an increase in the percentage of patients having the test 
or tempt staff to break with local policy and perform testing more 
frequently. The use of POC testing did not lead to any effect on 
treatment intensification, patient education or counselling. 
Surprisingly, the coverage of annual HbA1c testing in the diabetic 
population did not improve, despite the availability of POC testing. 
This may indicate that the way in which care is organised and how 
patients flow through the facilities have a greater impact on who is 
tested than the availability of POC testing.
Studies elsewhere have clearly shown that POC testing during the 
same visit can be associated with improved glycaemic control.[7,8] In 
the SA public sector primary care context, however, this was not the 
case. There appeared to be a high level of clinical inertia in the face 
of clear and immediate evidence of poor control. A lack of clinical 
responsiveness could be due to poor understanding of the clinical 
guidelines, lack of confidence, or reluctance to follow the guidelines, 
particularly the initiation of insulin. Interventions that required 
addi tional time or commitment might have been avoided in the face 
of the high workload. Nurses, who provide the bulk of chronic care, 
may have lacked the capability to manage poor glycaemic control. 
Local studies have shown a significant lack of knowledge about 
lifestyle modification among nurses,[12] and the implementation of 
new guidelines elsewhere in the Western Cape has also had little 
impact on treatment intensification.[13] In chronic care for HIV it was 
necessary to clearly identify and implement a different response to 
treatment failure to overcome similar clinical inertia.[14] High levels of 
burnout have also been reported among local healthcare providers, 
which may impact on their capacity to implement new treatments or 
counselling.[15] Strengthening of primary care providers and systems 
may therefore be needed before POC testing could have an effect on 
quality of care.
Studies have also shown that patient satisfaction is improved 
using POC testing, and personal knowledge of one’s HbA1c level 
is associated with better outcomes.[16] The qualitative feedback from 
the chronic care teams suggested that patients were more satisfied 
with POC testing, although the immediate feedback did not appear 
to improve self­care or adherence to the point of impacting on 
glycaemic control.
POC testing was feasible and relatively easy to perform and 
integrate into the organisation of care. It was associated with a small 
incremental cost, which given the lack of effectiveness in this study, 
would not be worth the investment in the current context. 
Adherence to the quality control measures was poor, although the 
tests that were performed suggested that the results were reliable. If 
POC testing were introduced, greater supervision of technical quality 
would be needed.
The design of the study was quasi­experimental. One of its 
limitations is the lack of random allocation to intervention or control 
groups, which makes the possibility of confounding factors more 
likely. The presence of confounding factors in the organisation of 
care or behaviour of healthcare workers is seen in the unexpected 
improvement of counselling in the control group. More organised or 
less organised chronic care teams might have responded differently 
to the provision and use of the POC tests. It is possible, therefore, 
that different results could have been obtained if different health 
centres were selected. Nevertheless, it was thought that these health 
centres typically reflected the current organisation and quality of 
care in the public sector. As the quality of medical records was 
sometimes inadequate, the researchers struggled to extract the 
necessary information from these records. 
Conclusion
This study does not support the implementation of POC testing for 
HbA1c in the current public sector primary care context, as it did not 
lead to greater coverage, intensified treatment, more counselling or 
improved glycaemic control. There was a significant improvement 
in patients receiving immediate feedback on their HbA1c result. 
POC testing was feasible, easy to perform and integrate into the 
organisation of care, and was associated with a negligible incremental 
cost. The feedback suggests that POC testing for HbA1c is feasible 
in primary care settings in the Western Cape. Future studies should 
explore the effect of introducing POC testing with interventions to 
strengthen primary care and overcome clinical inertia.
Acknowledgements. This work is based on research supported by the 
National Research Foundation of South Africa and the Chronic Disease 
Initiative for Africa. We thank the chronic care teams at all the study sites 
and Siemens for donation of the POC analysers. We also acknowledge 
Drs R Machekano and T Esterhuizen from the Biostatistics Unit, Faculty 
of Medicine and Health Sciences, Stellenbosch University for their help 
with data analysis.
1240       December 2016, Vol. 106, No. 12
RESEARCH
1. International Diabetes Federation. Diabetes Atlas. 6th ed. Brussels: IDF, 2013. http://www.idf.org/ 
(accessed 14 October 2016).
2. Daramola K, Mash B. The validity of monitoring the control of diabetes with random blood glucose 
testing. S Afr Fam Pract 2013;55(6):79­580. http://dx.doi.org/10.1080/20786204.2013.10874420
3. Amod A, Ascott­Evans BH, Berg GI, et al. The 2012 SEMDSA Guideline for the management of type 2 
diabetes. JEMDSA 2012;17(2):S83­S84.
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macro­vascular and micro­
vascular complications of type 2 diabetes (UKPDS 35). BMJ 2000;321(7258):405­412. http://dx.doi.
org/10.1136/bmj.321.7258.405 
5. American Diabetes Association. American Diabetes Guidelines 2007: Standards of medical care in 
Diabetes. Position statement. Diabetes Care 2007;30(Suppl 1):S4­S41. http://dx.doi.org/10.2337/dc07­S004
6. Leal S, Soto­Rowen M. Usefulness of point of care testing in the treatment of dia betes in an underserved 
population. J Diabetes Sci Technol 2009;3(4):672­676.   http://dx.doi.org/10.1177/193229680900300409
7. Khunti K, Stone MA, Burden AC, et al. A randomized controlled trial of near patient testing for 
glycated haemoglobin in patients with type 2 diabetes. Br J Gen Pract 2006;56(528):511­517. 
8. Rust G, Gailor M, Daniels E, McMillan­Persuad B, Strothers H, Mayberry R. Point of care testing 
to improve glycaemic control. Int J Health Care Qual Assur 2008;21(3):325­335. http://dx.doi.
org/10.1108/09526860810868256
9. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HBA1c level improves glycaemic control in 
type 1 and insulin treated type 2 diabetic patients. Diabetes Care 1999;22(11):1785­1789. http://dx.doi.
org/10.2337/diacare.22.11.1785
10. Brown JB, Harris SB, Webster­Bogaert S, Porter S. Point­of­care testing in diabetes management: What 
role does it play? Diabetes Spectrum 2004;17(4):244­248. http://dx.doi.org/10.2337/diaspect.17.4.244
11. De Vries E. Integrated Chronic Disease Audit Report. Cape Town: Department of Health, 2014.
12. Parker WA, Steyn NP, Levitt NS, et al. They think they know but do they? Misalignment of perceptions 
of lifestyle modification knowledge among health professionals. Public Health Nutr 2011;14(8):1429­
1438. http://dx.doi.org/10.1017/S1368980009993272 
13. Chronic Disease Initiative for Africa. Chronic Disease Initiative Annual Report. 2014. Pragmatic 
cluster randomised controlled trial of a guideline­based intervention to improve the primary care of 
non­communicable diseases in the Eden and Overberg districts of the Western Cape. http://www.cdia.
uct.ac.za (accessed 1 March 2016).
14. Médecins Sans Frontières. Khayelitsha. Supporting adherence to antiretroviral treatment: A facility 
approach to reduce the risk of treatment failure. https://www.msf.org.za/sites/msf.org.za/files/risk_of_
treatment_failure_mentorship_toolkit_v3.pdf (accessed 10 November 2016).
15. Rossouw L, Seedat S, Emsley RA, Suliman S, Hagemeister D. The prevalence of burnout and depression 
in medical doctors working in the Cape Town Metropolitan Municipality community healthcare 
clinics and district hospitals of the Provincial Government of the Western Cape: A cross­sectional 
study. S Afr Fam Pract 2013;55(6)567­573. http://dx.doi.org/10.1080/20786204.2013.10874418
16. Laurence CO, Gialamas A, Bubner TT, et al. Point of care testing in general practice trial 
management group. Patient satisfaction with point of care testing in general practice. Br J Gen Pract 
2010;60:e98­e104. http://dx.doi.org/10.3399%2Fbjgp10X483508
Accepted 29 September 2016.
